180 related articles for article (PubMed ID: 12460878)
21. A comparison of simvastatin and atorvastatin up to maximal recommended doses in a large multicenter randomized clinical trial.
Illingworth DR; Crouse JR; Hunninghake DB; Davidson MH; Escobar ID; Stalenhoef AF; Paragh G; Ma PT; Liu M; Melino MR; O'Grady L; Mercuri M; Mitchel YB;
Curr Med Res Opin; 2001; 17(1):43-50. PubMed ID: 11464446
[TBL] [Abstract][Full Text] [Related]
22. Rosuvastatin activates ATP-binding cassette transporter A1-dependent efflux ex vivo and promotes reverse cholesterol transport in macrophage cells in mice fed a high-fat diet.
Shimizu T; Miura S; Tanigawa H; Kuwano T; Zhang B; Uehara Y; Saku K
Arterioscler Thromb Vasc Biol; 2014 Oct; 34(10):2246-53. PubMed ID: 25104799
[TBL] [Abstract][Full Text] [Related]
23. Effects of low-dose atorvastatin and rosuvastatin on plasma lipid profiles: a long-term, randomized, open-label study in patients with primary hypercholesterolemia.
Mazza F; Stefanutti C; Di Giacomo S; Vivenzio A; Fraone N; Mazzarella B; Bucci A
Am J Cardiovasc Drugs; 2008; 8(4):265-70. PubMed ID: 18690760
[TBL] [Abstract][Full Text] [Related]
24. Effect of atorvastatin on apolipoprotein B48 metabolism and low-density lipoprotein receptor activity in normolipidemic patients with coronary artery disease.
Dane-Stewart CA; Watts GF; Pal S; Chan D; Thompson P; Hung J; Mamo JC
Metabolism; 2003 Oct; 52(10):1279-86. PubMed ID: 14564679
[TBL] [Abstract][Full Text] [Related]
25. High-density lipoprotein apolipoprotein A-I kinetics: comparison of radioactive and stable isotope studies.
Ooi EM; Watts GF; Farvid MS; Chan DC; Allen MC; Zilko SR; Barrett PH
Eur J Clin Invest; 2006 Sep; 36(9):626-32. PubMed ID: 16919045
[TBL] [Abstract][Full Text] [Related]
26. Expression of human hepatic lipase in the rabbit model preferentially enhances the clearance of triglyceride-enriched versus native high-density lipoprotein apolipoprotein A-I.
Rashid S; Trinh DK; Uffelman KD; Cohn JS; Rader DJ; Lewis GF
Circulation; 2003 Jun; 107(24):3066-72. PubMed ID: 12796142
[TBL] [Abstract][Full Text] [Related]
27. Atorvastatin increases HDL cholesterol by reducing CETP expression in cholesterol-fed APOE*3-Leiden.CETP mice.
de Haan W; van der Hoogt CC; Westerterp M; Hoekstra M; Dallinga-Thie GM; Princen HM; Romijn JA; Jukema JW; Havekes LM; Rensen PC
Atherosclerosis; 2008 Mar; 197(1):57-63. PubMed ID: 17868678
[TBL] [Abstract][Full Text] [Related]
28. Atorvastatin and fenofibrate combination induces the predominance of the large HDL subclasses and increased apo AI fractional catabolic rates in New Zealand white rabbits with exogenous hypercholesterolemia.
Flores-Castillo C; Zamora-Pérez JÁ; Carreón-Torres E; Arzola-Paniagua A; Aguilar-Salinas C; López-Olmos V; Fragoso JM; Luna-Luna M; Rodríguez-Pérez JM; Franco M; Vargas-Alarcón G; Pérez-Méndez Ó
Fundam Clin Pharmacol; 2015 Aug; 29(4):362-70. PubMed ID: 25982284
[TBL] [Abstract][Full Text] [Related]
29. Effects of atorvastatin on the HDL subpopulation profile of coronary heart disease patients.
Asztalos BF; Horvath KV; McNamara JR; Roheim PS; Rubinstein JJ; Schaefer EJ
J Lipid Res; 2002 Oct; 43(10):1701-7. PubMed ID: 12364554
[TBL] [Abstract][Full Text] [Related]
30. Effects of different doses of atorvastatin on human apolipoprotein B-100, B-48, and A-I metabolism.
Lamon-Fava S; Diffenderfer MR; Barrett PH; Buchsbaum A; Matthan NR; Lichtenstein AH; Dolnikowski GG; Horvath K; Asztalos BF; Zago V; Schaefer EJ
J Lipid Res; 2007 Aug; 48(8):1746-53. PubMed ID: 17526934
[TBL] [Abstract][Full Text] [Related]
31. Effects of atorvastatin versus fenofibrate on apoB-100 and apoA-I kinetics in mixed hyperlipidemia.
Bilz S; Wagner S; Schmitz M; Bedynek A; Keller U; Demant T
J Lipid Res; 2004 Jan; 45(1):174-85. PubMed ID: 14523053
[TBL] [Abstract][Full Text] [Related]
32. Pharmacodynamics and pharmacokinetic-pharmacodynamic relationships of atorvastatin, an HMG-CoA reductase inhibitor.
Stern RH; Yang BB; Hounslow NJ; MacMahon M; Abel RB; Olson SC
J Clin Pharmacol; 2000 Jun; 40(6):616-23. PubMed ID: 10868312
[TBL] [Abstract][Full Text] [Related]
33. Comparisons of effects of statins (atorvastatin, fluvastatin, lovastatin, pravastatin, and simvastatin) on fasting and postprandial lipoproteins in patients with coronary heart disease versus control subjects.
Schaefer EJ; McNamara JR; Tayler T; Daly JA; Gleason JL; Seman LJ; Ferrari A; Rubenstein JJ
Am J Cardiol; 2004 Jan; 93(1):31-9. PubMed ID: 14697462
[TBL] [Abstract][Full Text] [Related]
34. Pioglitazone increases the fractional catabolic and production rates of high-density lipoproteins apo AI in the New Zealand White Rabbit.
Carreón-Torres E; Juárez-Meavepeña M; Cardoso-Saldaña G; Gómez CH; Franco M; Fievet C; Luc G; Juárez-Oropeza MA; Pérez-Méndez O
Atherosclerosis; 2005 Aug; 181(2):233-40. PubMed ID: 16039276
[TBL] [Abstract][Full Text] [Related]
35. Effect of decreased plasma cholesterol by atorvastatin treatment on erythrocyte mechanical properties.
Uyuklu M; Meiselman HJ; Baskurt OK
Clin Hemorheol Microcirc; 2007; 36(1):25-33. PubMed ID: 17211059
[TBL] [Abstract][Full Text] [Related]
36. Effects of high doses of simvastatin and atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I.
Crouse JR; Frohlich J; Ose L; Mercuri M; Tobert JA
Am J Cardiol; 1999 May; 83(10):1476-7, A7. PubMed ID: 10335764
[TBL] [Abstract][Full Text] [Related]
37. Effect of atorvastatin on SR-BI expression and HDL-induced cholesterol efflux in adipocytes of hypercholesterolemic rabbits.
Zhao SP; Wu ZH; Hong SC; Ye HJ; Wu J
Clin Chim Acta; 2006 Mar; 365(1-2):119-24. PubMed ID: 16185675
[TBL] [Abstract][Full Text] [Related]
38. Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome.
Watts GF; Barrett PH; Ji J; Serone AP; Chan DC; Croft KD; Loehrer F; Johnson AG
Diabetes; 2003 Mar; 52(3):803-11. PubMed ID: 12606523
[TBL] [Abstract][Full Text] [Related]
39. Role of the kidney in regulating the metabolism of HDL in rabbits: evidence that iodination alters the catabolism of apolipoprotein A-I by the kidney.
Braschi S; Neville TA; Maugeais C; Ramsamy TA; Seymour R; Sparks DL
Biochemistry; 2000 May; 39(18):5441-9. PubMed ID: 10820016
[TBL] [Abstract][Full Text] [Related]
40. Analysis of particle size and lipid composition as determinants of the metabolic clearance of human high density lipoproteins in a rabbit model.
Lamarche B; Uffelman KD; Steiner G; Barrett PH; Lewis GF
J Lipid Res; 1998 Jun; 39(6):1162-72. PubMed ID: 9643347
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
